0 Nightingale Pharma (2025) Limited 16199030 false 2025-01-21 2026-01-31 2026-01-31 The principal activity of the company is research and experimental development on biotechnology Digita Accounts Production Advanced 6.30.9574.0 true 16199030 2025-01-21 2026-01-31 16199030 2026-01-31 16199030 bus:Micro-entities 2025-01-21 2026-01-31 16199030 bus:AuditExemptWithAccountantsReport 2025-01-21 2026-01-31 16199030 bus:FilletedAccounts 2025-01-21 2026-01-31 16199030 bus:SmallCompaniesRegimeForAccounts 2025-01-21 2026-01-31 16199030 bus:RegisteredOffice 2025-01-21 2026-01-31 16199030 bus:Director1 2025-01-21 2026-01-31 16199030 bus:PrivateLimitedCompanyLtd 2025-01-21 2026-01-31 16199030 countries:England 2025-01-21 2026-01-31 xbrli:pure iso4217:GBP

Registration number: 16199030

Nightingale Pharma (2025) Limited

Unaudited Filleted Financial Statements

for the Period from 21 January 2025 to 31 January 2026

 

Nightingale Pharma (2025) Limited

(Registration number: 16199030)
Balance Sheet as at 31 January 2026

2026
£

Current assets

1

Capital and reserves

1

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
166 College Road
Harrow
Middlesex
HA1 1BH

These financial statements were authorised for issue by the director on 20 October 2026.

2

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 0.

For the financial period ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

•

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

•

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the micro entities regime and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 20 October 2026
 

.........................................
Dr D I Slovick
Director